HomeCONGRESS

CONGRESS

View Category
Day 3

SWISS AMI: Stem cells infusion after primary angioplasty

The trial enrolled 200 patients post AMI treated with successful PCI, with LVEF ≤45% randomized to placebo,...
solaci -
Learn More
Day 1

FAME 2: Cost-effectiveness of FFR-guided angioplasty in patients with stable angina

Introduction: FAME study 2, presented at the European Congress of Cardiology 2012, is a multicenter study that...
solaci -
Learn More
Day 1

TRILOGY ACS. Prasugrel versus clopidogrel in patients with acute coronary syndromes with non – ST segment elevation treated clinically after angiographic evaluation

Insides : 40%-60% of patients with acute coronary syndrome with non ST elevation (ACS) are treated clinically....
solaci -
Learn More
Day 2

PHS II Trial: Use of multivitamins in the prevention of cardiovascular disease in men.

Observational studies have shown contradicting results on the use of multivitamins. PHS II is the only randomized...
solaci -
Learn More
Day 2

GAUSS trial: Antibodies for the treatment of hypercholesterolemia in patients with statin intolerance.

Statins are the most effective treatment to reduce LDL levels and cardiovascular risk, 10-20% of patients are...
solaci -
Learn More
Day 3

TIME: Use and duration of bone marrow derived stem cells infusion for the treatment of post infarction ventricular dysfunction.

This study randomized 120 patients with acute myocardial infarction after successful primary angioplasty with a residual ejection...
solaci -
Learn More
Day 3

POSEIDON: Transendocardial infusion of autologous vs. allogeneic mesenchymal stem cells in patients with ischemic cardiomyopathy.

Safety and efficacy of autologous vs. allogeneic mesenchymal stem cells had not yet been compared. This trial...
solaci -
Learn More
Day 3

SCIPIO trial: Intracoronary infusion of autologous cardiac stem cells improve ventricular function.

This is the first trial that used autologous cardiac stem cells for the treatment of ischemic cardiomyopathy....
solaci -
Learn More